Figure 1 | Scientific Reports

Figure 1

From: The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients

Figure 1

Concentration-dependent decline of cardiac contractility in auxotonically contracting human atrial trabeculae upon sorafenib administration. Original analogue recordings of developed force with increasing (1–30 µM) concentrations of sorafenib (a) and after sorafenib wash-out (b). Summary data (c). n = 9/10 trabeculae (control/sorafenib) from 11 hearts; *p < 0.05 vs. baseline (Lmax) by Friedman’s repeated measures one-way ANOVA on ranks (ANOVA p < 0.001) and p < 0.01 vs. control by Student’s t-test, #p < 0.05 vs. 30 µM sorafenib and p = 0.68 vs. baseline (Lmax) by paired t-test.

Back to article page